Recent Updates
Recently added Catalysts
MDGL Positive Sentiment Score: 70/100

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Wednesday, January 3, 2024 1 min read
Key Takeaway: Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company focused on treating nonalcoholic steatohepatitis (NASH), announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2024. The presentation will be available via webcast, with a recorded version accessible after the event. Madrigal aims to highlight its lead therapy, resmetirom, which is designed to address key factors contributing to NASH.

Market Sentiment Analysis

POSITIVE FACTORS

  • Madrigal Pharmaceuticals is actively engaging with the investment community by presenting at a notable healthcare conference.
  • The webcast will provide accessibility to a wider audience, enhancing corporate visibility.
  • Madrigal's lead candidate, resmetirom, targets a high unmet medical need in NASH, indicating potential for impactful innovation.

Full Press Release Details

CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 pm PT.
The presentation will be webcast and an archived recording will be available for replay in the Investors section of the Madrigal website after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a liver-directed THR-β agonist oral therapy that is designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

Tags

Frequently Asked Questions

When will Madrigal Pharmaceuticals present at the J.P. Morgan Conference?

Madrigal will present on January 10, 2024, at 4:30 PM PT.

Is the presentation at the conference live or recorded?

The presentation will be webcast live and archived for later viewing.

What disease is Madrigal targeting with its therapeutics?

Madrigal is focused on developing therapies for nonalcoholic steatohepatitis (NASH).

What is Madrigal's lead candidate for NASH?

The lead candidate is resmetirom, a liver-directed THR-β agonist.

Where can more information about Madrigal be found?

More information is available on Madrigal's website, www.madrigalpharma.com.

Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals NASH J.P. Morgan Healthcare Conference resmetirom biopharmaceuticals
Last updated: Jan 3, 2024